1. What is it?
Semax is a seven-amino-acid peptide developed from a fragment of ACTH, with a short peptide segment added. Structural similarity does not mean it acts like the whole natural hormone or is identical to acetylated Semax derivatives. Check the exact name when reading publications: a Semax finding cannot automatically establish effects of N-Acetyl Semax or further modifications. [144] [143]
2. Why do people turn to it?
The most common expectations around Semax concern memory, focus and brain protection. Some readers also seek information about recovery after a stroke. These are different goals. The clinical publication described people after an ischaemic stroke, meaning brain damage caused by inadequate blood supply. It did not study healthy people preparing for an exam. Results from neurological rehabilitation should therefore not be turned into promises of faster learning or greater productivity. [141] [142]
3. How does it work?
In a rat study, Semax affected BDNF and its related signalling system. BDNF is a protein involved in nerve cell function and adaptation. Such findings help guide further research. They do not directly show that a person will remember better or that their brain will repair itself after injury. An increase in blood BDNF is also not equivalent to confirmation that damaged brain structures have been rebuilt. [142] [141]
4. What do studies actually show?
A 2018 paper described 110 people after a stroke, grouped according to the stage of rehabilitation and whether they received Semax. Assessments included movement, independence in everyday activities and blood BDNF levels. The authors reported favourable results associated with Semax and earlier rehabilitation. However, the English abstract does not provide enough detail to establish whether treatment was allocated at random, or whether participants and assessors knew who received Semax. This is an important limitation when judging what actually accounted for the improvement. [141]
5. What do we still not know?
Function after stroke can improve through rehabilitation, time and standard treatment. If groups differ in important ways, separating an additional product's effects from those factors is difficult. One favourable study account is therefore insufficient to establish standard treatment. Rat experiments also differ from human treatment. Neither an animal mechanism nor a clinical observation after stroke confirms all online promises about concentration. [141] [142]
6. What are the risks?
A full human safety profile of Semax is lacking, especially for long-term use and different forms. The FDA highlighted insufficient data on its behaviour in the human body and possible immune reactions. A small study reporting no clear problem cannot exclude rarer complications. The natural origin of the fragment that inspired the peptide also does not guarantee that the synthetic product is harmless. [143] [141]
7. Is it an approved medicine?
FDA documentation states that Semax is an approved medicine in Russia. This does not imply Polish approval or confirmation of all online claims. Semax is not FDA-approved, and we do not present it as EMA-approved. The HHS proposal announced on 30 October 2026 concerns separate US preparation rules, not Semax approval. It replaces neither effectiveness studies nor EU regulatory decisions. [143] [146]
8. What is new in research?
In 2026, FDA published a Semax assessment for an advisory committee. It found insufficient evidence for assessed uses, including cerebral ischaemia and migraine, and safety gaps. This is a new review of existing evidence, not a new positive treatment trial. The 2018 post-stroke paper and 2006 rat experiment remain older sources and should not be presented as fresh confirmation of effectiveness. [143] [141] [142]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
Rat experiment; online 22 September 2006; PubMed abstract reviewed · DOI: 10.1016/j.brainres.2006.07.108. Accessed: 3 November 2026.
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]
Post-stroke clinical study; 2018; English PubMed abstract reviewed; full Russian article not reviewed · DOI: 10.17116/jnevro20181183261-68. Accessed: 3 November 2026.
- FDA Briefing Document: Semax — Related Bulk Drug Substances
Regulatory assessment for the 23–24 July 2026 meeting; identity, assessment scope, effectiveness, safety and final conclusions reviewed. Accessed: 3 November 2026.
- Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties
Chemical and cell study of Ac-Semax; online 27 August 2016; full PubMed abstract reviewed, not the full paper · DOI: 10.1016/j.jinorgbio.2016.08.013. Accessed: 3 November 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
Original HHS notice in the Federal Register; 30.10.2026; the entire draft-policy notice was read; this is not FDA medicine approval. Accessed: 03.11.2026.